Please note: Next Awareness Night is Nov. 14.

Hormone Therapy

Finasteride does not increase risk of prostate cancer death

May 20, 2018

The landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens’ risk of getting prostate cancer without increasing their risk of dying from the disease. Initial study findings suggested there may be a link between use of the drug and a more lethal form of prostate cancer, but […]

Read the article or watch the video →

No Benefit for Aggressive Therapy in Metastatic Prostate Cancer

April 2, 2018

For men with metastatic prostate cancer there is no survival advantage for aggressive therapy over conservative androgen deprivation therapy only, according to a study. Read the article here.

Read the article or watch the video →

Finasteride can reduce prostate cancer risk long term

April 2, 2018

A drug used to treat enlarged prostate or hair loss in men has been shown to have a long-term protective effect against prostate cancer. Read the article here.

Read the article or watch the video →

Success of abiraterone trials prompts ‘mind shift’ in prostate cancer treatment

November 5, 2017

Abiraterone acetate is poised to challenge docetaxel as the standard addition to androgen deprivation therapy for treatment of newly diagnosed, metastatic castration-resistant prostate cancer. Read the article here.

Read the article or watch the video →

Prostate cancer: Could a breast cancer drug reduce recurrence

November 5, 2017

A new study suggests that combining a breast cancer drug with hormone therapy could be a more effective strategy to reduce the progression and recurrence of prostate cancer in men. Read the article here.

Read the article or watch the video →

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

July 2, 2017

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. Read the […]

Read the article or watch the video →

Biolyse Pharma stymied in effort to make cheaper version of pricey prostate cancer drug

April 9, 2017

A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price. Right now Xtandi costs U.S. patients as much as $129,000 US a year, or about $90 per pill. St. Catharines, Ont.-based Biolyse Pharma says it can make the […]

Read the article or watch the video →

Psychological Effects From ADT a Growing Challenge in Prostate Cancer

February 19, 2017

Androgen-deprivation therapy (ADT) can be associated with significant psychological effects in patients with prostate cancer. Additionally, these side effects—which include depression, Alzheimer disease, and coronary disease—are often under-reported by patients. Read the article here.

Read the article or watch the video →

Prostate Cancer Treatment Can Raise Dementia Risk

February 19, 2017

Reducing testosterone levels with androgen deprivation therapy, or A.D.T., is a common treatment for prostate cancer. But a new study has found that it more than doubles the risk of dementia. Read the article here.

Read the article or watch the video →

ADT May Increase Depression Risk in Prostate Cancer

July 3, 2016

When elderly men with localized prostate cancer are given androgen-deprivation therapy (ADT), the risk of depression and hospitalization for psychiatric treatment is significantly increased, a population-based study of 78,000 U.S. men showed. Read the article.

Read the article or watch the video →